Literature DB >> 27909836

Febuxostat and tumor lysis syndrome: an indication that remains unclear.

F Vincent1, A Dupré2, C Mousseaux2, C Bornstain2, M Darmon3,4,5.   

Abstract

Entities:  

Year:  2016        PMID： 27909836     DOI： 10.1007/s10147-016-1070-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  9 in total

1.  Urate oxidase should remain mandatory in patients at high risk of tumor lysis syndrome.

Authors:  Michael Darmon; Aurelie Bourmaud; François Vincent
Journal:  Am J Kidney Dis       Date:  2014-01       Impact factor: 8.860

2.  Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol.

Authors:  P R Band; D S Silverberg; J F Henderson; R A Ulan; R H Wensel; T K Banerjee; A S Little
Journal:  N Engl J Med       Date:  1970-08-13       Impact factor: 91.245

3.  Extreme hyperphosphataemia causing acute anuric nephrocalcinosis in lymphosarcoma.

Authors:  A Kanfer; G Richet; J Roland; F Chatelet
Journal:  Br Med J       Date:  1979-05-19

4.  Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.

Authors:  Kazuo Tamura; Yasukazu Kawai; Toru Kiguchi; Masataka Okamoto; Masahiko Kaneko; Makoto Maemondo; Kenichi Gemba; Katsumichi Fujimaki; Keita Kirito; Tetsuya Goto; Tomoaki Fujisaki; Kenji Takeda; Akihiro Nakajima; Takanori Ueda
Journal:  Int J Clin Oncol       Date:  2016-03-26       Impact factor: 3.402

5.  Acute renal failure from xanthine nephropathy during management of acute leukemia.

Authors:  Christopher LaRosa; Laura McMullen; Suzanne Bakdash; Demetrius Ellis; Lakshmanan Krishnamurti; Hsi-Yang Wu; Michael L Moritz
Journal:  Pediatr Nephrol       Date:  2006-10-13       Impact factor: 3.714

6.  Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy.

Authors:  J D Conger; S A Falk
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

7.  Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?

Authors:  Emmanuel Canet; Morgane Cheminant; Lara Zafrani; Catherine Thieblemont; Lionel Galicier; Etienne Lengline; David Schnell; Danielle Reuter; Michael Darmon; Benoit Schlemmer; Elie Azoulay
Journal:  Leuk Lymphoma       Date:  2014-02-24

8.  Prognostic significance of acute renal injury in acute tumor lysis syndrome.

Authors:  Michael Darmon; Isabelle Guichard; François Vincent; Benoit Schlemmer; Elie Azoulay
Journal:  Leuk Lymphoma       Date:  2010-02

9.  Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.

Authors:  Michael Darmon; François Vincent; Laurent Camous; Emmanuel Canet; Caroline Bonmati; Thorsten Braun; Denis Caillot; Jérôme Cornillon; Sophie Dimicoli; Anne Etienne; Lionel Galicier; Alice Garnier; Stéphane Girault; Mathilde Hunault-Berger; Jean-Pierre Marolleau; Philippe Moreau; Emmanuel Raffoux; Christian Recher; Anne Thiebaud; Catherine Thieblemont; Elie Azoulay
Journal:  Br J Haematol       Date:  2013-06-15       Impact factor: 6.998
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.